These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9160582)

  • 1. Single-site findings in a study of the safety and efficacy of a CCKB receptor antagonist, CI-988, in the treatment of generalized anxiety disorder.
    Sramek JJ; Costa JF; Adams JB; Macpherson A; Cutler NR
    Anxiety; 1994-1995; 1(5):242-3. PubMed ID: 9160582
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of CI-988, a cholecystokinin-B receptor antagonist, on lactate-induced panic.
    Cowley DS; Adams JB; Pyke RE; Cook J; Zaccharias P; Wingerson D; Roy-Byrne PP
    Biol Psychiatry; 1996 Sep; 40(6):550-2. PubMed ID: 8879478
    [No Abstract]   [Full Text] [Related]  

  • 3. A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder.
    Adams JB; Pyke RE; Costa J; Cutler NR; Schweizer E; Wilcox CS; Wisselink PG; Greiner M; Pierce MW; Pande AC
    J Clin Psychopharmacol; 1995 Dec; 15(6):428-34. PubMed ID: 8748432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Suppression of conditioned fear by administration of CCKB receptor antagonist PD135158].
    Tsutsumi T; Isogawa K; Kouno Y; Hikichi T; Nagayama H; Akiyoshi J
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Feb; 18(1):15-8. PubMed ID: 9592807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients.
    van Megen HJ; Westenberg HG; den Boer JA; Slaap B; van Es-Radhakishun F; Pande AC
    Psychopharmacology (Berl); 1997 Feb; 129(3):243-8. PubMed ID: 9084062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers.
    Bradwejn J; Koszycki D; Paradis M; Reece P; Hinton J; Sedman A
    Biol Psychiatry; 1995 Dec; 38(11):742-6. PubMed ID: 8580227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of conditioned fear by administration of CCKB receptor antagonist PD135158.
    Tsutsumi T; Akiyoshi J; Isogawa K; Kohno Y; Hikichi T; Nagayama H
    Neuropeptides; 1999 Dec; 33(6):483-6. PubMed ID: 10657528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurochemical actions of CCK underlying the therapeutic potential of CCK-B antagonists.
    Hughes J; Hunter JC; Woodruff GN
    Neuropeptides; 1991 Jul; 19 Suppl():85-9. PubMed ID: 1679213
    [No Abstract]   [Full Text] [Related]  

  • 9. A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group.
    Lydiard RB; Ballenger JC; Rickels K
    J Clin Psychiatry; 1997; 58 Suppl 11():11-8. PubMed ID: 9363043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
    Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
    Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder.
    Pande AC; Greiner M; Adams JB; Lydiard RB; Pierce MW
    Biol Psychiatry; 1999 Sep; 46(6):860-2. PubMed ID: 10494457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies.
    Pollack MH; Tiller J; Xie F; Trivedi MH
    J Clin Psychopharmacol; 2008 Jun; 28(3):308-16. PubMed ID: 18480688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone.
    Pollack MH; Worthington JJ; Manfro GG; Otto MW; Zucker BG
    J Clin Psychiatry; 1997; 58 Suppl 11():19-23. PubMed ID: 9363044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CR 2945: a novel CCKB receptor antagonist with anxiolytic-like activity.
    Revel L; Mennuni L; Garofalo P; Makovec F
    Behav Pharmacol; 1998 May; 9(3):183-94. PubMed ID: 9832933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of a standardized herbal product from Galphimia glauca on generalized anxiety disorder. A randomized, double-blind clinical trial controlled with lorazepam.
    Herrera-Arellano A; Jiménez-Ferrer E; Zamilpa A; Morales-Valdéz M; García-Valencia CE; Tortoriello J
    Planta Med; 2007 Jul; 73(8):713-7. PubMed ID: 17562493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of central cholecystokinin receptor blockade on hypothalamic-pituitary-adrenal and symptomatic responses to overnight withdrawal from alprazolam.
    Abelson JL; Curtis GC; Nesse R; Fantone R; Pyke RE; Bammert-Adams J
    Biol Psychiatry; 1995 Jan; 37(1):56-9. PubMed ID: 7893861
    [No Abstract]   [Full Text] [Related]  

  • 17. Switching from benzodiazepines to buspirone using a tapered overlap method in generalized anxiety disorder.
    Arató M
    J Clin Psychiatry; 2001 Aug; 62(8):657-8. PubMed ID: 11561943
    [No Abstract]   [Full Text] [Related]  

  • 18. CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies.
    Harro J
    Amino Acids; 2006 Oct; 31(3):215-30. PubMed ID: 16738800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early response and 8-week treatment outcome in GAD.
    Rynn M; Khalid-Khan S; Garcia-Espana JF; Etemad B; Rickels K
    Depress Anxiety; 2006; 23(8):461-5. PubMed ID: 16845651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, placebo-controlled study with tofizopam in anxiety neurosis.
    Filip V; Sladka R; Dostalova J; Haskovcova V; Jarosova M; Faltus F; Slanska J
    Agressologie; 1981 Oct; 22(C):27-30. PubMed ID: 6119918
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.